Pfizer to pursue companion diagnostic for Oxford BioMedica's 5T4 programme
This article was originally published in Scrip
Executive Summary
Oxford BioMedica has signed an amendment to broaden its licensing agreement with Pfizer regarding the development of therapeutic products which target the 5T4 tumour antigen for the treatment of cancer.